According to the consolidated financial statements, Farmak increased its export deliveries by 40% last year, having shipped products to 35 countries.
The share of exports in the Company’s total sales in 2020 reached 29.6%, which is 5.3% more than last year. The Company’s products are sold in the EU, Central and South America, the CIS, the Middle East, Asia etc.
Since the beginning of the pandemic, there has been a sharp increase in the demand throughout the world for medicinal products that are used in the complex therapy of COVID-19 patients. They include corticosteroids, relaxants, analgesics, antibiotics, as well as anaesthetics and sedatives required when using lung ventilators. Thus, a large number of Farmak products have been exported to Israel, Great Britain, Sweden, France, Germany, Poland, Australia, New Zealand, Mexico and Singapore, as well as delivered for the WHO (World Health Organization) use.
Due to the European GMP certificates, in addition to national ones, issued regarding Farmak’s manufacturing lines, the Company may sell its products in countries with particularly strict regulatory requirements.
“Farmak is a company with state-of-the-art, high-tech facilities that manufacture medicinal products in compliance with all international standards. Due to this, we guarantee the high quality of our products and gain the trust of consumers all around the world. We are now preparing for FDA* inspection to enter the U.S. market. Our strategic goal is to increase the share of exports in total sales to 40%,” said Volodymyr Kostiuk, Chief Executive Officer of JSC Farmak.
Farmak has been recognized as the best exporter of the year**.
It is worth reminding that JSC Farmak has its own representative offices in Kazakhstan, Uzbekistan, Belarus and Kyrgyzstan and the marketing company in Poland.
* U.S. Food and Drug Administration
** the best exporter of the year among large enterprises of Kyiv in: “Manufacturing of basic pharmaceutical products and pharmaceuticals” in 2019, according to the Kyiv Chamber of Commerce and Industry.
Farmak took the fourth place in the sustainable development rating published by Korrespondent.net. The rating was developed and compiled by experts of Dengi.ua and Korrespondent.net in partnership with the UN Global Compact Network Ukraine. The evaluation of all rating participants was based on ESG (Environmental, Social and Corporate Governance) criteria. T...
reputation management quality In mid-May 2021, PR-Service agency presented the data on the annual rating Reputational ACTIVists. Farmak took the second place among pharmaceutical manufacturers and importers operating in Ukraine. Corporate reputation management quality rating has been compiled for more than 15 years. As the organizers say, the rating i...
At the beginning of 2021, the representatives of the Republic of Belarus inspected Farmak’s manufacturing, warehouse, laboratory facilities and the functioning of its pharmaceutical quality system. Following the inspection, the Company’s facilities engaged in manufacturing of finished medicinal products have got the EAEU GMP Certificate. The EAEU GMP Certifi...